10-Q quarterly report · filed Nov 9, 2026

Claritev Corp (CTEV) Q3 2026 10-Q Quarterly Report

Short answer

Claritev Corp (CTEV) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $268M (up 9.1% year over year) with net income of −$62M.

Q3 2026 key financials · XBRL

Revenue
$268M
+9.1% YoY · +4.2% QoQ
Net income
−$62M
+11.4% YoY · −4.3% QoQ
Operating margin
7.7%
EPS (diluted)
−$3.64
+13.9% YoY · −4.6% QoQ

Source: XBRL data from the Claritev Corp (CTEV) Q3 2026 10-Q on SEC EDGAR. USD.

Claritev Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $268.3M, up 9.1% YoY from $246.0M
  • Operating margin 7.7% vs 4.1% YoY, net loss $61.8M vs $69.8M
  • Best segment: Claims intelligence revenue $192.5M, up 17.1%; worst: Payment and revenue integrity $25.9M, down 9.8%
  • Cash balance $23.0M, operating cash flow $65.0M, investing outflow $128.8M
  • Outlook: liquidity sufficient for next twelve months, with technology investments and antitrust legal expenses as headwinds

Risk Factors

  • DOJ civil investigative demand received May 19, 2026, with inquiry ongoing after separate antitrust proceeding closure
  • Regulatory risk: evolving healthcare laws may increase litigation exposure for cost management providers
  • Legal risk: provider and member litigation increasingly multi-party, multi-claim, or class-wide
  • Financial risk: uninsured or insufficiently insured litigation losses could materially affect results

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Claritev Corp quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.